Phase Ia study to evaluate GDC-6036 monotherapy in patients with colorectal cancer (CRC) with KRAS G12C mutation

J. Desai,S-W. Han, M. D. Forster,T. W. Kim,G. Alonso Casal,E. Shacham Shmueli, S. E. Bowyer,M. J. De Miguel,A. Falcon Gonzalez,R. H. Jones, M. G. Krebs,W. H. Miller, L. Paz-Ares, P. Lorusso,A. Sacher,N. Dharia, M. T. Lin, J. L. Schutzman,Z. Shi,M. Patel

ANNALS OF ONCOLOGY（2022）

引用 4|浏览1

暂无评分

摘要

The oncogenic KRAS G12C mutation is found in ∼4% CRC patients (pts). GDC-6036 is an oral, highly potent and selective KRAS G12C inhibitor, with robust tumor growth inhibition in multiple preclinical models.

查看译文

关键词

colorectal cancer,monotherapy,mutation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要